Sign In
Free Newsletter
Actavis gets FDA approval for new generic
Actavis Inc. said today it has received Food and Drug Administration approval of its abbreviated new drug application for its treatment for opioid dependence. The drug is the generic equivalent of Reckitt Benckiser's Suboxone.
Finding corrections for soaring health care costs
Health care executives often say implementing new models of care means having one foot in the old world of health care and another in the new. The transition is slow because of the difficulty of finding evidence that new models work in the real world, both to improve care and cut costs.
Hoping tax credit helps angels give startups wings
New Jersey hopes a new tax credit helps it become a hub for high-tech jobs across hot fields like bio-
technology, medical devices and renewable energy.
State continues quest to lower end-of-life care costs
Another tool has been added to the roster for decreasing the cost of end-of-life care and increasing compliance with patients' wishes.
Capsugel launches business unit to expand offerings
Capsugel, of Morristown, announced Thursday the launch of its Dosage Form Solutions business unit to focus on lipid-based formulations of its technology, while continuing to expand its offerings in targeted release capsules.
Eisai gets 65M for U.S. rights to Targretin
Eisai Inc.’s U.S. operations announced today that it sold the U.S. rights to its Targretin capsules and gel to Montreal-based Valeant Pharmaceuticals International Inc.
Insurers realize enormity of challenges posed by health exchanges
Experts say time is short for the government to build the technology to run and operate the exchange — and to educate thousands of individuals and small-business owners on how to shop for complex health insurance plans.
Celgene announces 600 million share repurchase program
Summit-based life sciences company Celgene Corp. announced today it is repurchasing $600 million in shares of its common stock through an accelerated repurchase agreement with an investment bank.
Merck partnering with S. Korean firm to develop biosimilars
Merck & Co., in the Whitehouse Station section of Readington, announced today an agreement with Samsung Bioepis Co. Ltd. to develop and commercialize several biosimilar candidates.
Terumo brings urology distribution in house
A New Jersey medical device firm is gearing up for expansion.
Savient partnering with Swedish firm to market arthritis treatment
Savient Pharmaceuticals Inc., in Bridgewater, announced today it is partnering with Sobi, of Stockholm, to promote Kineret, a treatment for rheumatoid arthritis, in the United States.
Holy Name recognized for care efforts in Haiti
When a devastating earthquake hit Haiti in 2010, Holy Name Medical Center was in a good position to help, as over the past two decades, it has built a presence at Hopital Sacre Coeur, in Milot, about a four-hour drive from Port-au-Prince.
